DR CALUX®
dioxins
mode/action
bioassay
procedure
properties
ER CALUX®
estrogens
mode/action
bioassay
procedure
properties
| Derived from studying the toxicological mode of action of estrogens
and pseudo estrogens, BDS developed an in vitro bioassay to screen for estrogenicity
and anti-estrogenicity based on the receptor-mediated mechanism of action of estrogens
in a wide variety of matrices. The Estrogen Responsive - Chemically Activated LUciferase eXpression (ER CALUX®) assay comprises a genetically modified T47D human breast adenocarcinoma cell expressing an endogenous estrogen receptor. |
|
 ER CALUX® | Bioassay construct |
These stably transfected cells, have the firefly luciferase gene incorporated and coupled to EREs as a reporter gene for the presence of estrogenic substances. Cells that are exposed to estrogens or pseudo-estrogens not only express proteins that are under normal circumstances associated to the ERE, but in addition luciferase. By addition of the appropriate substrate for luciferase, light is emitted. The amount of light produced is proportional to the amount of ligand-ER binding which can be related to estradiol equivalents (EEQs). [back up] |
||
|
 |
|